News and insights

Subscribe to our newsletter

At first glance, the two tumor subtypes seem to have little in common: one takes root in the ovaries and the other, in breast tissue. Conventionally, tumors like these are referred to by their organ of origin and other basic characteristics such as the cell type that spawned them. But through projects like The Cancer Genome Atlas (TCGA), researchers from the Ó³»­´«Ã½ and elsewhere are taking a deeper look at cancer’s many forms and finding genomic similarities that cut across these classifications, as well as great diversity within single classes of cancer.

A layer cake? No, not interactive enough. A spinning wheel? Too mechanistic. What about a film strip? No, that’s not quite right either.

Ó³»­´«Ã½ researcher Nir Yosef and scientific illustrator Sigrid Knemeyer were in search of the perfect metaphor to communicate the complex scientific concepts encapsulated in a paper by Yosef and his colleagues. The two spoke by phone and over email, exchanging ideas about how to capture the paper’s main messages

Five scientists from the Ó³»­´«Ã½ and its partners have won federal grants to pursue projects with the potential to transform scientific research and more rapidly bring biomedical advances to patients.

The National Institutes of Health is awarding approximately $155 million to 81 researchers across the country who are pursuing visionary science through its High Risk High Reward program, supported by the NIH Common Fund.

A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients.

Squamous cell lung cancer kills more people each year than breast, colorectal, or prostate cancer, ranking second only to lung adenocarcinoma in the number of deaths it causes. But unlike the most common form of lung cancer, squamous cell carcinoma has no treatments aimed at the specific genetic alterations that drive it.